284462-39-1 Usage
Derivative of isoindole-1,3(2H)-dione
It is a modified version of the parent compound isoindole-1,3(2H)-dione, with additional functional groups or substitutions.
5-(4-aminophenoxy) substitution
The compound has a 4-aminophenoxy group attached to the 5-position of the isoindole-1,3(2H)-dione core.
Heterocyclic organic compound
The compound contains one or more heteroatoms (atoms other than carbon) within its ring structure, in this case, nitrogen and oxygen.
Five-membered ring structure
The compound has a five-membered ring in its core structure, which includes two nitrogen atoms and one oxygen atom.
Potential applications in chemical and pharmaceutical industries
Due to its unique structure and properties, the compound may be used in various chemical reactions or as an intermediate in the synthesis of pharmaceuticals.
Properties and uses vary depending on the specific application and context
The behavior and reactivity of the compound may differ based on the conditions it is used in, and its potential applications may be diverse, ranging from synthesis to drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 284462-39-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,4,4,6 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 284462-39:
(8*2)+(7*8)+(6*4)+(5*4)+(4*6)+(3*2)+(2*3)+(1*9)=161
161 % 10 = 1
So 284462-39-1 is a valid CAS Registry Number.
284462-39-1Relevant articles and documents
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
-
Page/Page column 9, (2010/01/31)
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
-
, (2008/06/13)
This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.